Cognition Therapeutics, Inc. Stock Analysis & AI Score
Cognition Therapeutics, Inc. (CGTX) has an ST Score of 52.3 (B-), driven by its Forecast (A) and held back by its Momentum (C-). Analysts rate it Buy with a $3.00 price target (+215.5% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Cognition Therapeutics, Inc. (CGTX) has an ST Score of 52.3 (B-), driven by its Forecast (A) and held back by its Momentum (C-). Analysts rate it Buy with a $3.00 price target (+215.5% upside).
- Strongest
- ForecastA
- Weakest
- MomentumC-
All factor grades
- ForecastA
- ValuationA-
- Financial StrengthB
- GrowthB
- ProfitabilityC-
- MomentumC-
- Piotroski1/9
Contact
CGTX stock: frequently asked questions
What is CGTX's ST Score?
Cognition Therapeutics, Inc. (CGTX) has an ST Score of 52.3 (B-), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is CGTX a buy, hold, or sell?
Analysts rate CGTX a Buy, with a price target of $3.00 (+215.5% vs the current price). Our ST Score grades it B- (52.3/100). The ST Score is a data-driven signal, not a recommendation.
What are CGTX's factor grades?
Valuation A-, Profitability C-, Financial Strength B, Momentum C-, Growth B, Forecast A.
What is CGTX's valuation grade?
Cognition Therapeutics, Inc. (CGTX) earns a valuation grade of A-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is CGTX's growth grade?
Cognition Therapeutics, Inc. (CGTX) earns a growth grade of B, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is CGTX's profitability grade?
Cognition Therapeutics, Inc. (CGTX) earns a profitability grade of C-, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is CGTX's financial strength grade?
Cognition Therapeutics, Inc. (CGTX) earns a financial strength grade of B, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for CGTX?
The average analyst price target for Cognition Therapeutics, Inc. (CGTX) is $3.00 from 7 analysts, which is +215.5% versus the recent price of $0.95.
What is CGTX's Piotroski score?
Cognition Therapeutics, Inc. (CGTX) has a Piotroski F-Score of 1 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.